Last reviewed · How we verify
Infliximab Treatment
At a glance
| Generic name | Infliximab Treatment |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Colitis Ulcerative
- Drug ineffective
- Arthralgia
- Nasopharyngitis
- Maternal exposure during pregnancy
- Hypersensitivity
- Infusion related reaction
- Pneumonia
- NASOPHARYNGITIS
- TONSILLITIS
- ASTHENIA
- Skin reaction
Key clinical trials
- Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease (NA)
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infliximab Treatment CI brief — competitive landscape report
- Infliximab Treatment updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI